Krebs Biochemicals & Industries Ltd

Krebs Biochemicals & Industries Ltd has touched a new 52-week low, closing just 2.22% above its lowest price of Rs 48.1, marking a significant milestone in its ongoing decline. Despite a modest 1.23% gain over the past two days, the stock remains under pressure, trading below all key moving averages amid a challenging market environment.

Krebs Biochemicals & Industries Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.48.1 today, marking a significant decline in its stock price amid broader market movements and company-specific performance factors.

Krebs Biochemicals & Industries Ltd has declined to a new 52-week low, closing near Rs 52.5, marking a significant drop in its share price amid ongoing financial pressures and subdued market performance within the Pharmaceuticals & Biotechnology sector.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 Feb 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 13 March 2026, providing investors with the latest insights into its performance and prospects.

Krebs Biochemicals & Industries Ltd has declined to a new 52-week low, closing just 1.27% above its lowest price of Rs 50.5. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the share price retreating sharply after a brief two-day rally.

Krebs Biochemicals & Industries Ltd’s share price declined sharply to a new 52-week low of Rs.50.5 on 6 March 2026, marking a significant downturn amid broader sector and market pressures. The stock underperformed its Pharmaceuticals & Biotechnology sector peers and the broader market, reflecting ongoing financial and performance concerns.

Krebs Biochemicals & Industries Ltd has reached a new 52-week low, trading at Rs 57.08, marking a significant decline in its stock price over the past year. This development reflects ongoing pressures on the company’s financial performance and market valuation within the Pharmaceuticals & Biotechnology sector.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 19 February 2026, providing investors with the latest insights into its performance and prospects.

Krebs Biochemicals & Industries Ltd. reported a catastrophic third quarter for FY2026, with net losses widening to ₹3.13 crores despite a sequential improvement from the disastrous ₹6.14 crore loss in Q2 FY26. The Visakhapatnam-based active pharmaceutical ingredient (API) manufacturer, which operates one of the world's few fermentation-based production facilities, continues to grapple with severe operational challenges as revenue plummeted 36.62% year-on-year to ₹7.27 crores in Q3 FY26. The stock has reflected this deteriorating fundamental picture, collapsing 45.96% over the past year and trading at ₹55.62 as of February 9, 2026—down 51.17% from its 52-week high of ₹113.90.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed below reflect the company’s current position as of 08 February 2026, providing investors with the latest insights into its performance and outlook.

Krebs Biochemicals & Industries Ltd has touched a new 52-week low of Rs.51 today, marking a significant decline in its stock price amid persistent downward momentum. This latest low reflects ongoing challenges faced by the company within the Pharmaceuticals & Biotechnology sector, with the stock underperforming both its sector peers and broader market indices over the past year.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 28 January 2026, providing investors with the most recent and relevant data to assess the stock’s outlook.

Krebs Biochemicals & Industries Ltd has reached a new 52-week low, reflecting ongoing pressures on the stock amid a challenging market environment and subdued company performance. The stock's latest decline to this significant price level underscores persistent headwinds within the Pharmaceuticals & Biotechnology sector.

Krebs Biochemicals & Industries Ltd has touched a new 52-week low of Rs.60.17 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance issues.

Krebs Biochemicals & Industries Ltd has reached a new 52-week low, reflecting ongoing pressures on the stock amid subdued financial performance and sector underperformance. The stock’s latest decline to this significant price level underscores persistent challenges faced by the company in the Pharmaceuticals & Biotechnology sector.

Krebs Biochemicals & Industries Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 05 January 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Krebs Biochemicals & Industries Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 06 February 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 25 December 2025, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.